In silico Mutagenesis and Modeling of Decoy Peptides Targeting CIB1 to
Obscure its Role in Triple-negative Breast Cancer Progression

Muhammad      Shahab; Chaoqun      Liang; Xiuyuan      Duan; Guojun      Zheng; Abdul      Wadood

doi:10.2174/1381612829666230327162852

Abstract

Background: Cancer is recognized globally as the second-most dominating and leading cause of morbidities. Breast cancer is the most often diagnosed disease in women and one of the leading causes of cancer mortality. In women, 287,850, and in males, 2710 cases were reported in 2022. Approximately 10-20% of all new cases of breast cancer diagnosed in the United States in 2017 were triple-negative breast cancers (TNBCs), which lack the expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2).

Objective: This study aims to adopt different strategies for targeting calcium integrin-binding protein 1 by computer- aided drug design methods. Our results showed that the top four selected peptides interact with CIB1 more strongly than the reference peptide and restore normal cell function by engaging CIB1. Our binding affinity analyses explore an innovative approach to planning a new peptide to inhibit triple-negative breast cancer.

Methods: Molecular dynamic simulation of the CIB1-UNC10245092 interaction highlights the potential peptide inhibitors through in-silico mutagenesis and designs novel peptide inhibitors from the reference peptide (UNC10245092) through residue scan methodology.

Results: The top four designed peptides (based on binding free energy) were subjected to molecular dynamics simulations using AMBER to evaluate stability.

Conclusion: Our results indicate that among the top five selected peptides, the mutant 2nd mutants have more potential to inhibit CIB1 than the reference peptide (UNC10245092) and have the potency to prevent or restore the tumor suppressor function of UNC10245092.

« Previous

[1]
Blows FM, Driver KE, Schmidt MK, et al. Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: A collaborative analysis of data for 10,159 cases from 12 studies. PLoS Med  2010; 7(5): e1000279.
 [http://dx.doi.org/10.1371/journal.pmed.1000279] [PMID: 20520800]

[2]
Lehmann BD, Bauer JA, Chen X, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest  2011; 121(7): 2750-67.
 [http://dx.doi.org/10.1172/JCI45014] [PMID: 21633166]

[3]
Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: Clinical features and patterns of recurrence. Clin Cancer Res  2007; 13(15): 4429-34.
 [http://dx.doi.org/10.1158/1078-0432.CCR-06-3045] [PMID: 17671126]

[4]
Lee A, Djamgoz MBA. Triple negative breast cancer: Emerging therapeutic modalities and novel combination therapies. Cancer Treat Rev  2018; 62: 110-22.
 [http://dx.doi.org/10.1016/j.ctrv.2017.11.003] [PMID: 29202431]

[5]
Mirzoeva OK, Das D, Heiser LM, et al. Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition. Cancer Res  2009; 69(2): 565-72.
 [http://dx.doi.org/10.1158/0008-5472.CAN-08-3389] [PMID: 19147570]

[6]
Gordon V, Banerji S. Molecular pathways: PI3K pathway targets in triple-negative breast cancers. Clin Cancer Res  2013; 19(14): 3738-44.
 [http://dx.doi.org/10.1158/1078-0432.CCR-12-0274] [PMID: 23748695]

[7]
Naik UP, Patel PM, Parise LV. Identification of a novel calcium-binding protein that interacts with the integrin alphaIIb cytoplasmic domain. J Biol Chem  1997; 272(8): 4651-4.
 [http://dx.doi.org/10.1074/jbc.272.8.4651] [PMID: 9030514]

[8]
Yuan W, Leisner TM, McFadden AW, et al. CIB1 is an endogenous inhibitor of agonist-induced integrin αIIbβ3 activation. J Cell Biol  2006; 172(2): 169-75.
 [http://dx.doi.org/10.1083/jcb.200505131] [PMID: 16418530]

[9]
Rusnak F, Mertz P. Calcineurin: Form and function. Physiol Rev  2000; 80(4): 1483-521.
 [http://dx.doi.org/10.1152/physrev.2000.80.4.1483] [PMID: 11015619]

[10]
Gentry HR, Singer AU, Betts L, et al. Structural and biochemical characterization of CIB1 delineates a new family of EF-hand-containing proteins. J Biol Chem  2005; 280(9): 8407-15.
 [http://dx.doi.org/10.1074/jbc.M411515200] [PMID: 15574431]

[11]
Tahara E Jr, Tahara H, Kanno M, et al. G1P3, an interferon inducible gene 6-16, is expressed in gastric cancers and inhibits mitochondrial-mediated apoptosis in gastric cancer cell line TMK-1 cell. Cancer Immunol Immunother  2005; 54(8): 729-40.
 [http://dx.doi.org/10.1007/s00262-004-0645-2] [PMID: 15685448]

[12]
Yuan W, Leisner TM, McFadden AW, et al. CIB1 is essential for mouse spermatogenesis. Mol Cell Biol  2006; 26(22): 8507-14.
 [http://dx.doi.org/10.1128/MCB.01488-06] [PMID: 16982698]

[13]
Naik MU, Pham NT, Beebe K, Dai W, Naik UP. Calcium-dependent inhibition of polo-like kinase 3 activity by CIB1 in breast cancer cells. Int J Cancer  2011; 128(3): 587-96.
 [http://dx.doi.org/10.1002/ijc.25388] [PMID: 20473878]

[14]
Nagayoshi Y, Nakamura M, Matsuoka K, et al. Profiling of autoantibodies in sera of pancreatic cancer patients. Ann Surg Oncol  2014; 21(S3): 459-65.
 [http://dx.doi.org/10.1245/s10434-014-3574-0] [PMID: 24585405]

[15]
Heineke J, Auger-Messier M, Correll RN, et al. CIB1 is a regulator of pathological cardiac hypertrophy. Nat Med  2010; 16(8): 872-9.
 [http://dx.doi.org/10.1038/nm.2181] [PMID: 20639889]

[16]
Blazejczyk M, Wojda U, Sobczak A, et al. Ca2+-independent binding and cellular expression profiles question a significant role of calmyrin in transduction of Ca2+-signals to Alzheimer’s disease-related presenilin 2 in forebrain. Biochim Biophys Acta Mol Basis Dis  2006; 1762(1): 66-72.
 [http://dx.doi.org/10.1016/j.bbadis.2005.09.006] [PMID: 16257512]

[17]
Shahab M, Wadood A, Zheng G. Strategies for targeting CIB1: A challenging drug target. Curr Pharm Des  2022; 28(28): 2348-8.

[18]
Sussman JL, Lin D, Jiang J, et al. Protein Data Bank (PDB): Database of three-dimensional structural information of biological macromolecules. Acta Crystallogr D Biol Crystallogr  1998; 54(6): 1078-84.
 [http://dx.doi.org/10.1107/S0907444998009378] [PMID: 10089483]

[19]
Molecular operating environment (MOE). Chemical Computing Group Inc. 2016.

[20]
Kortemme T, Kim DE, Baker D. Computational alanine scanning of protein-protein interfaces. Sci STKE  2004; 2004(219): pl2-2.
 [http://dx.doi.org/10.1126/stke.2192004pl2] [PMID: 14872095]

[21]
Massova I, Kollman PA. Combined molecular mechanical and continuum solvent approach (MM-PBSA/GBSA) to predict ligand binding. Perspect Drug Discov Des  2000; 18(1): 113-35.
 [http://dx.doi.org/10.1023/A:1008763014207]

[22]
Bro R, Smilde AK. Principal component analysis. Anal Methods  2014; 6(9): 2812-31.
 [http://dx.doi.org/10.1039/C3AY41907J]

[23]
Amadei A, Linssen ABM, Berendsen HJC. Essential dynamics of proteins. Proteins  1993; 17(4): 412-25.
 [http://dx.doi.org/10.1002/prot.340170408] [PMID: 8108382]

[24]
Ying-Chang Liang , Chin FPS. Downlink channel covariance matrix (DCCM) estimation and its applications in wireless DS-CDMA systems. IEEE J Sel Areas Comm  2001; 19(2): 222-32.
 [http://dx.doi.org/10.1109/49.914500]

Rights & Permissions Print Cite

Journal Information

For Authors

For Editors

For Reviewers

Explore Articles

Open Access

Open Access Articles

For Visitors

DOI https://dx.doi.org/10.2174/1381612829666230327162852	Print ISSN 1381-6128
Publisher Name Bentham Science Publisher	Online ISSN 1873-4286

Current Pharmaceutical Design

In silico Mutagenesis and Modeling of Decoy Peptides Targeting CIB1 to Obscure its Role in Triple-negative Breast Cancer Progression

Abstract Play Pause

Related Journals

Related Books

Abstract